Lexaria Bioscience Corp. (NASDAQ:LEXX) said on November 19, 2026 that dosing and final participant visits had been completed as scheduled in Human Pilot Study #7, identified as GLP-1-H26-7. The 5-week study is examining two oral DehydraTECH-semaglutide, or DHT-sema, formulations alongside Novo’s commercially available Wegovy® tablets.
With the final blood samples collected, the remaining work includes laboratory testing, quality-control procedures, a review of the study data and preparation of a report. Lexaria said study information will not be shared with third parties until the data has completed that review process. The company plans to issue further information after the review and quality-control work is finished.
#Three-arm design compares tablet and capsule formats
The study has three arms and is assessing safety, tolerability and pharmacokinetic properties. The Lexaria formulations contain SNAC and are being tested in both tablet and capsule forms, with the results compared against Wegovy® tablets.
Participants received the study products under fasted pre-dose conditions, which Lexaria said are similar to the advised administration criteria for Novo’s oral semaglutide products. The company selected the 5-week dosing period because it expects that duration to allow semaglutide concentrations in the study arms to reach steady-state levels, where drug input and natural elimination are balanced.
GLP-1-H26-7 is the first Lexaria human study to assess an oral tablet DHT-sema formulation. Earlier DehydraTECH GLP-1 studies used capsule formulations. Lexaria said the tablet design incorporates certain physical characteristics associated with the SNAC-inclusive tablet delivery approach used in Novo’s Rybelsus® and Wegovy® products.
The study also represents the first time Lexaria’s DHT-sema tablet and capsule formulations containing SNAC are being assessed over a multi-dose, multi-week period in humans. Human Pilot Studies #1 and #2, designated GLP-1-H24-1 and GLP-1-H24-2, included SNAC but used single-dose designs and did not use tablets. Those studies were conducted in 2024 and 2025.
Lexaria says its DehydraTECH™ platform is a patented formulation and processing technology intended for oral drug delivery. The company operates a licensed in-house research laboratory and says it has 70 patents granted, with additional patents pending worldwide. Lexaria said GLP-1-H26-7 is fully funded through existing corporate resources.
No results from GLP-1-H26-7 have been reported in the announcement. Lexaria said there is no assurance that the proposed uses, benefits or advantages of its patented and patent-pending technology will be realised. The company also identified risks related to regulation and regulatory approvals, scientific discovery, the patent process, possible adverse effects from testing or product use, and delays or cancellations affecting research and development.
The release stated that its claims had not been evaluated by the Food and Drug Administration. It also said Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
Lexaria Bioscience Corp. announced that final dosing and final participant visits for Human Pilot Study #7, GLP-1-H26-7, had been completed on schedule. The study is evaluating two oral DehydraTECH-semaglutide compositions against Novo's commercially available Wegovy® tablets over a 5-week duration.
The study evaluates two oral DehydraTECH-semaglutide, or DHT-sema, compositions against commercially available Wegovy® tablets. It is assessing safety and tolerability, as well as pharmacokinetic properties, across the study arms.
Lexaria Bioscience Corp. says the study has three separate arms. The arms compare SNAC-inclusive DHT-sema compositions in tablet and capsule formats with commercially available Wegovy® tablets.
The study used a 5-week dosing duration. Lexaria says this period was selected to allow semaglutide blood quantities in each arm to be expected to reach steady-state concentration levels, meaning drug input is balanced with natural bodily elimination.
The study work will now move to laboratory sample analyses, quality control, review of all data and reporting. Lexaria says no study information will be provided to third parties until the data has been reviewed and quality controlled, after which it will provide further information.
For the first time, Lexaria Bioscience Corp. is evaluating an oral tablet DHT-sema composition rather than using only capsule compositions. The company says it has attempted to mimic and integrate certain physical properties of the SNAC-inclusive tablet delivery modality used by Novo's Rybelsus® and Wegovy® products.
Both Lexaria Bioscience Corp.'s DHT-sema tablet and capsule test articles are formulated with SNAC, which the company says is the first time these formulations will be evaluated over a multi-dose, multi-week period in humans. Earlier Human Pilot Studies #1 and #2, GLP-1-H24-1 and GLP-1-H24-2, incorporated SNAC but used single-dose designs and did not use tablets.
The study is being conducted under fasted pre-dose conditions similar to the advised administration criteria for Novo's oral semaglutide products. It includes DHT-sema compositions in both tablet and capsule formats alongside Wegovy® tablets.
Lexaria Bioscience Corp. says the study is fully funded from existing corporate resources.
Lexaria Bioscience Corp. describes itself as a global innovator in drug delivery platforms. Its patented DehydraTECH™ formulation and processing technology is designed for oral delivery and, according to the company, has evidenced the ability to increase bio-absorption, reduce side-effects and deliver some drugs more effectively across the blood-brain barrier.
Lexaria Bioscience Corp. trades on NASDAQ under the ticker symbol LEXX, as stated in the announcement.
Lexaria Bioscience Corp. says it holds 70 patents granted and additional patents pending worldwide. The company also operates a licensed in-house research laboratory.
Lexaria Bioscience Corp. says there is no assurance that the postulated uses, benefits or advantages of its patented and patent-pending technology will be realised, and states that its forward-looking statements involve risks including regulation, regulatory approvals, scientific discovery, patent processes, potential adverse effects from testing or product use, and delays or cancellations of planned research and development. The company also says no statement in the release has been evaluated by the Food and Drug Administration and that Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.